Twist Bioscience Corporation (NASDAQ:TWST) finished Friday with a subtraction of -$0.48 to close at $22.31, a downside of -2.11 percent. An average of 1,084,760 shares of common stock have been traded in the last five days. There was a fall of -$0.67 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,151,230 shares traded, while the 50-day average volume stands at 1,186,316.
TWST stock has decreased by -4.54% in the last month. The company shares reached their 1-month lowest point of $20.46 on 08/03/23. With the stock rallying to its 52-week high on 02/02/23, shares of the company touched a low of $11.46 and a high of $57.40 in 52 weeks. It has reached a new high 9 times so far this year and lost -6.30% or -$1.50 in price. In spite of this, the price is down -61.13% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
TWST stock investors should be aware that Twist Bioscience Corporation (TWST) stock had its last reported insider trading activity 184 days ago on May 10. In this transaction, the insider spent $45,820. Director, JOHANNESSEN JAN, disposed of 1,732 shares at a price of $26.45 on Feb 09. The insider now owns more than $45,820 worth of shares. Prior to that, Banyai William went on to Sale 292 shares at $24.05 each on Jan 04. An amount of $7,023 was transacted.
Valuation Metrics
Twist Bioscience Corporation (TWST) stock’s beta is 1.26. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.03, the price-to-book (PB) ratio at 1.80.
Financial Health
The quick ratio of Twist Bioscience Corporation for the three months ended June 29 was 6.20, and the current ratio was 6.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Twist Bioscience Corporation’s EBITDA margin for the year ending June 29 is -104.33%, while its operating margin for the same period stands at -96.10%. Its gross profit as reported stood at $84.23 million compared to revenue of $203.56 million.
Earnings Surprise
For the three-month period that ended June 29, Twist Bioscience Corporation had $49.69 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$57.4 million in the quarter, while revenues of -$59.16 million were shrunk -5.44%. The analyst consensus anticipated Twist Bioscience Corporation’s latest quarter earnings to come in at -$1.14 per share, but it turned out to be -$1.01, a 11.40% surprise. For the quarter, EBITDA amounted to -$52.29 million. Shareholders own equity worth $57.4 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Twist Bioscience Corporation (TWST) price momentum. RSI 9-day as of the close on 11 August was 44.88%, suggesting the stock is Neutral, with historical volatility in this time frame at 79.61%.
As of today, TWST’s price is $22.96 -2.92% or -$0.67 from its 5-day moving average. TWST is currently trading -4.25% lower than its 20-day SMA and +35.05% higher than its 100-day SMA. However, the stock’s current price level is +47.26% above the SMA50 and -23.28% below the SMA200.
The stochastic %K and %D were 30.53% and 35.36%, respectively, and the average true range (ATR) was 1.63. With the 14-day stochastic at 26.81% and the average true range at 1.61, the RSI (14) stands at 48.95%. The stock has reached 0.04 on the 9-day MACD Oscillator while the 14-day reading was at -0.92.
Analyst Ratings
Scotiabank launched coverage on Twist Bioscience Corporation (NASDAQ: TWST) in its analyst report released on January 05, 2023. The firm assigned the stock a Sector outperform rating. The consensus rating for Twist Bioscience Corporation (TWST) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell TWST, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 5 others rate it as a “buy”.
What is TWST’s price target for the next 12 months?
Analysts predict a range of price targets between $19.00 and $33.00, with a median target of $26.50. Taking a look at these predictions, the average price target given by analysts for Twist Bioscience Corporation (TWST) stock is $26.25.
